H-Index
38
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
Medical Science Monitor Basic Research

AmJCaseRep
MedSciTechnol

eISSN: 2329-0358

Rescue therapy with intravenous silibinin in liver transplant recipients with recurrent HCV hepatitis – two case reports

Łukasz Socha, Ewa Karpińska, Krzysztof Jurczyk, Łukasz Laurans, Dorota Bander, Marta Lachtara, Marta Wawrzynowicz-Syczewska

Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland

Ann Transplant 2014; 19:161-164

DOI: 10.12659/AOT.889779

Available online: 2014-04-08

Published: 2014-04-08


Abstract: Background: Recurrence of hepatitis C virus (HCV) infection after liver transplantation is inevitable and decreases survival. Graft loss due to recurrent HCV occurs in 25% to 30% of patients. The recommended AASLD treatment is PEG-IFN, with or without ribavirin, but some patients might be not eligible for this treatment. An alternative antiviral agent is silibinin (SIL). In vitro silibinin stops replication, probably by inhibiting HCV RNA polymerase.
Case Report: We present the cases of 2 patients with severe recurrent HCV infection who received intravenous silibinin (IV SIL) as a “rescue therapy”. In the first patient with cholestatic fibrosing hepatitis, HCV RNA became undetectable. We also noted significant viremia reduction, and improvement in laboratory results and clinical presentation in the second patient.
Conclusions: Administration of IV SIL resulted in a rapid decrease of HCV viremia. In post-transplant patients with HCV recurrence who are not eligible for standard antiviral treatment, IV SIL can be considered as an alternative, but further investigations are necessary to establish treatment protocols.

Keywords: cholestatic fibrosing hepatitis, hepatitis C reinfection, silibinin, Liver Transplantation



Back